Trevi Therapeutics Secures $15,000,000 New Funding Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=09bbd27d-d471-4e6f-aaa4-d58be5beef07
Date
1/8/2015
Company Name
Trevi Therapeutics
Mailing Address
195 Church Street 14th Floor New Haven, CT 06510 USA
Company Description
Trevi Therapeutics, Inc. is a drug development company founded in 2011 focused on developing T111 for the severe chronic itching condition known as pruritus. Pruritus is manifested in various dermatological, metabolic, hematologic and neuronal conditions.
Website
http://www.trevitherapeutics.com
Transaction Type
Debt
Transaction Amount
$15,000,000
Transaction Round
Undisclosed
Proceeds Purposes
This financing is an important step for Trevi as we complete the funding for our ongoing clinical trials of Nalbuphine ER in uremic pruritus and prurigo nodularis.
M&A Terms
Venture Investor
Venture Investor